Henry Schein (NASDAQ:HSIC) Stock Rating Lowered by Baird R W

Henry Schein (NASDAQ:HSIC) was downgraded by Baird R W from a “strong-buy” rating to a “hold” rating in a research report issued to clients and investors on Monday,Zacks.com reports.

A number of other analysts also recently issued reports on HSIC. Robert W. Baird reaffirmed a “neutral” rating and set a $72.00 price objective (down from $82.00) on shares of Henry Schein in a report on Monday. Leerink Partners set a $75.00 target price on Henry Schein in a research note on Monday. Evercore ISI lifted their price target on shares of Henry Schein from $72.00 to $78.00 and gave the stock an “in-line” rating in a research note on Wednesday, July 9th. Wells Fargo & Company cut their price objective on shares of Henry Schein from $80.00 to $75.00 and set an “equal weight” rating for the company in a research note on Tuesday, May 6th. Finally, Barrington Research decreased their target price on shares of Henry Schein from $90.00 to $86.00 and set an “outperform” rating on the stock in a research report on Tuesday, May 6th. Eight research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $78.36.

Henry Schein Price Performance

NASDAQ:HSIC opened at $70.64 on Monday. Henry Schein has a 52-week low of $60.56 and a 52-week high of $82.49. The stock has a fifty day moving average of $71.73 and a 200 day moving average of $71.33. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.75 and a current ratio of 1.38. The firm has a market capitalization of $8.60 billion, a price-to-earnings ratio of 22.08, a P/E/G ratio of 2.28 and a beta of 0.87.

Henry Schein (NASDAQ:HSIC) last released its quarterly earnings results on Monday, May 5th. The company reported $1.15 earnings per share for the quarter, beating the consensus estimate of $1.11 by $0.04. Henry Schein had a return on equity of 14.87% and a net margin of 3.21%. The firm had revenue of $3.17 billion for the quarter, compared to analysts’ expectations of $3.24 billion. During the same quarter last year, the firm posted $1.10 EPS. The company’s revenue was down .1% compared to the same quarter last year. On average, research analysts expect that Henry Schein will post 4.74 EPS for the current fiscal year.

Institutional Investors Weigh In On Henry Schein

A number of hedge funds and other institutional investors have recently bought and sold shares of HSIC. Guggenheim Capital LLC raised its position in shares of Henry Schein by 2.5% in the 4th quarter. Guggenheim Capital LLC now owns 6,428 shares of the company’s stock worth $445,000 after purchasing an additional 159 shares during the last quarter. Radnor Capital Management LLC raised its holdings in Henry Schein by 1.6% in the second quarter. Radnor Capital Management LLC now owns 11,415 shares of the company’s stock worth $834,000 after buying an additional 180 shares during the last quarter. UMB Bank n.a. lifted its stake in shares of Henry Schein by 23.2% in the first quarter. UMB Bank n.a. now owns 1,066 shares of the company’s stock worth $73,000 after buying an additional 201 shares in the last quarter. Humankind Investments LLC grew its holdings in shares of Henry Schein by 7.4% during the fourth quarter. Humankind Investments LLC now owns 3,057 shares of the company’s stock valued at $212,000 after buying an additional 211 shares during the last quarter. Finally, HB Wealth Management LLC increased its position in shares of Henry Schein by 1.5% during the first quarter. HB Wealth Management LLC now owns 15,419 shares of the company’s stock valued at $1,056,000 after acquiring an additional 226 shares in the last quarter. Hedge funds and other institutional investors own 96.62% of the company’s stock.

About Henry Schein

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.